Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, Schönau V, Simon D, Kleinert S, Baraliakos X, Braun J, Hueber A, Fleck M, Rubbert-Roth A, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Glaser C, Filkova M, Feist E, Burmester G, Karberg K, Strunk J, Canete J, Senolt L, Naredo E, Schett G (2022)
Publication Type: Conference contribution
Publication year: 2022
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 1067-1069
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
APA:
Rech, J., Kleyer, A., Ostergaard, M., Hagen, M., Mendez, L.V., Tascilar, K.,... Schett, G. (2022). Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study). In ARTHRITIS & RHEUMATOLOGY (pp. 1067-1069). HOBOKEN: WILEY.
MLA:
Rech, Jürgen, et al. "Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2022. 1067-1069.
BibTeX: Download